Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Original article

Point-of-care ultrasonography in the initial characterization of patients with COVID-19

Yale Tung-Chen a,b,∗, Ana Algora-Martín c, Rafael Llamas-Fuentes d, Pablo Rodríguez-Fuertes c, Ana María Martínez Virto c, Elena Sanz-Rodríguez e, Blanca Alonso-Martinez f, María Angélica Rivera Núñez c

a Department of Internal Medicine, Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, Spain
b Department of Medicine, Universidad Alfonso X El Sabio, Madrid, Spain
c Department of Emergency Medicine, Hospital Universitario La Paz, Madrid, Spain
d Department of Emergency Medicine, Hospital Universitario Reina Sofia, Córdoba, Spain
e Department of Emergency Medicine, Hospital Universitario 12 de Octubre, Madrid, Spain
f Department of Internal Medicine, Hospital Universitario Severo Ochoa, Leganés, Madrid, Spain

A R T I C L E   I N F O

Article history:
Received 17 October 2020
Accepted 10 December 2020
Available online 28 January 2021

Keywords:
Coronavirus disease 2019 (COVID-19)
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Point-of-care ultrasonography (POCUS)
Focused cardiac ultrasonography (FOCUS).

A B S T R A C T

Background: There is growing evidence regarding the imaging findings of coronavirus disease 2019 (COVID-19) in chest X-rays and computed tomography scans; however, their availability during this pandemic outbreak might be compromised. Currently, the role of point-of-care ultrasonography (POCUS) has yet to be explored.

Objectives: To describe the POCUS findings of COVID-19 in patients with the disease admitted to the emergency department (ED), correlating them with vital signs, laboratory and radiologic results, therapeutic decisions, and the prognosis.

Methods: Prospective study performed in the ED of 2 academic hospitals. Patients with highly suspected or confirmed COVID-19 underwent a lung ultrasonography (lung POCUS), focused cardiac ultrasound (FOCUS), and inferior vena cava (IVC) exam.

Results: Between March and April 2020, 96 patients were enrolled. The mean age was 68.2 years (SD 17.5). The most common findings in the lung POCUS were an irregular pleural line (63.2%), bilateral confluence (55.2%), and isolated B-lines (53.1%), which were associated with a positive RT-PCR (odds ratio 4.327; 95% CI 1.216–15.401; p < .001), and correlated with IL-6 levels (rho = 0.622; p = .002). The IVC negatively correlated with levels of expiratory pO2 (rho = −0.539; p = .014) and inspiratory pO2 (rho = −0.527; p = .017), and expiratory diameter positively correlated with troponin I (rho = 0.509; p = .03). After the POCUS exam, almost 20% of the patients had an associated condition that required a change in their treatment or management.

Conclusions: POCUS parameters have the potential to impact the diagnosis, management, and prognosis of patients with confirmed or suspected COVID-19.

© 2021 Elsevier España, S.L.U. All rights reserved.

La ecografía clínica en la caracterización inicial de los pacientes con COVID-19

R E S U M E N

Antecedentes: Existe una evidencia creciente con respecto a los hallazgos por imagen de la COVID-19, tanto en radiografías de tórax como en tomografía computarizada; sin embargo, la disponibilidad de estas técnicas durante la pandemia podría verse comprometida.

Objetivos: Describir los hallazgos en la ecografía en el punto de atención (POCUS) en pacientes con COVID-19 que consultaron en el servicio de urgencias (SU), correlacionándolos con signos vitales, resultados analíticos y radiológicos, decisiones terapéuticas y pronóstico.

* Corresponding author.
E-mail address: yale.tung@salud.madrid.org (Y. Tung-Chen).

https://doi.org/10.1016/j.medcli.2020.12.007
0025-7753/© 2021 Elsevier España, S.L.U. All rights reserved.
**Methods:** Estudio prospectivo realizado en los SU de dos hospitales académicos. Los pacientes con COVID-19 con alta sospecha o confirmada se sometieron a una ecografía pulmonar (POCUS pulmonar), una ecocardioscopia y una ecografía de la vena cava inferior (VCI).

**Resultados:** Entre marzo y abril del 2020, se reclutaron 96 pacientes. La edad media fue de 68,2 años (DE 17,5). Los hallazgos más comunes en el POCUS pulmonar fueron la línea pleural irregular (63,2%), las líneas B confluyentes bilateral (55,2%) y aisladas (53,1%), que se vincularon con una RT-PCR (odds ratio 4,327; IC 95% 1,216 a 15,401; p < 0,001), y se asoció con los niveles de interleucina-6 (IL-6) (p = 0,622; p = 0,002). La VCI se correlacionó negativamente con los niveles de pO2 espiratorio (p = − 0,539; p = 0,014) y pO2 inspiratorio (p = − 0,527; p = 0,017), y el diámetro espiratorio se relacionó positivamente con la troponina I (p = 0,509; p = 0,03). Después del examen POCUS, casi el 20% de los pacientes tenían una condición asociada que requería un cambio en el tratamiento o manejo previo.

**Conclusiones:** Los parámetros POCUS tienen el potencial de afectar el diagnóstico, manejo y pronóstico de pacientes con sospecha o confirmación de COVID-19.

© 2021 Elsevier España, S.L.U. Todos los derechos reservados.

**Introduction**

On March 11, 2020, the World Health Organization declared a pandemic caused by a novel coronavirus, named Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), spreading to more than 180 countries, with 37,418,821 confirmed cases and 1,076,818 deaths. Coronavirus disease 2019 (COVID-19) is a highly contagious illness caused by infection with SARS-CoV-2. In this emergency, the ability to quickly characterize a confirmed or suspected case is critical, given almost any emergency department will struggle to keep up with the increasing number of patients and the shortage of health resources.

The primary diagnostic method is reverse transcription polymerase chain reaction (RT-PCR) of the nucleic acid of SARS-CoV-2 in nasopharyngeal swabs. However, it has many limitations, such as low sensitivity and the technical difficulties associated with performing it.

Various studies have suggested that abnormalities as shown on computed tomography (CT) are highly sensitive for diagnosis of patients with COVID-19, and should be considered as a screening tool. Moreover, various clinical, laboratory, and imaging parameters have been associated with prognosis and have been used to guide therapy.

However, because these diagnostic, laboratory, and therapeutic resources might not be ubiquitously available, we need alternative modalities to more rapidly characterize our patients.

Point-of-care ultrasonography (POCUS) is ubiquitous and quickly performed following simple and easy to apply protocols; therefore, it can be performed in mild or even unstable patients, in various settings. The presence of subpleural consolidations, thickened pleural lines, and B-lines are highly specific for lung involvement affecting the interstitium (interstitial syndrome), which in these cases suggests the presence of COVID-19 pneumonia.

The role and impact of this technique in this pandemic has not yet been explored.

**Patients and methods**

This was a prospective study performed in the emergency department (ED) of 2 academic hospitals, conducted in accordance with the Declaration of Helsinki, and approved by the Research Ethics Committee of each University Hospital involved. Informed consent was obtained from each enrolled patient.

**Patient selection**

Patients admitted to the ED with a clinical suspicion of COVID-19 (temperature above 37.2 °C, acute respiratory symptoms, gastrointestinal symptoms, or fatigue) requiring X-ray for evaluation were included. We excluded patients <18 years or those who declined to participate. A convenience sample of patients who met these inclusion criteria were consecutively enrolled and prospectively studied.

Patients were followed-up the following week, either during hospitalization or after hospital discharge, as appropriate.

**Initial patient assessment**

The initial evaluation of the patients included recording their medical history (demographic data, comorbidities, medications); symptoms; physical exam (temperature, blood pressure, heart rate, respiratory rate, and oxygen saturation); chest X-ray; and laboratory tests (hemogram, basic metabolic panel [e.g., glucose, electrolytes, kidney function, liver enzymes], lactate dehydrogenase [LDH], ferritin, interleukin-6 [IL-6], C-reactive protein [CRP], procalcitonin, blood gases [lactate and pH], and coagulation [D-dimer, international normalized ratio, partial thromboplastin time, fibrinogen]).

Two radiology trainees with 2–4 years of experience reviewed and informed all chest X-ray under the supervision of a senior radiologist with more than 10 years of experience.

**Ultrasound data collection**

Two ultrasound fellowship-trained emergency physicians (experienced sonologists according to the American College of Emergency Physicians ultrasonographic guidelines, with more than 10 ultrasound exams performed per week, and 5 years of experience in performing and interpreting POCUS) performed all the ultrasound exams. Therefore, an opportunity sampling method was implemented for patient selection.

Participants underwent ultrasonographic measurement of the inferior vena cava (IVC) and a focused cardiac ultrasound (POCUS). A lung ultrasonography (LUS) was performed following a 12-zone protocol. Each intercostal space of the upper and lower parts of the anterior, lateral, and posterior regions of the left and right chest wall was carefully examined. Findings were defined and recorded as follows (Fig. 1):

- A-lines: horizontal reverberation artifacts parallel to the pleural line.
Fig. 1. Lung ultrasound showing the different signs (white arrow). A-lines: horizontal reverberation artifacts parallel to the pleural line (A); B-lines: hyperechoic vertical artifacts that arise from the pleural line, extending to the bottom of the screen without fading that erases the A-line artifact, that can converge (B) or be well demarcated (C); Irregular pleural line: indented or broken pleural line (D); Consolidations: subpleural hypoechoic areas surrounded by a hyperechoic artifact tail (E); Pleural effusion: anechoic space between the parietal and visceral pleura (F).

- Pleural effusion: a typically anechoic space between the parietal and visceral pleura.
- B-lines: hyperechoic vertical artifacts that arise from the pleural line, extending to the bottom of the screen without fading that erases the A-line artifact.
  o Confluent B-lines: multiple converging or coalescent B-lines.
  o Isolated B-lines: discrete, well demarcated B-lines.
- Irregular pleural line: indented or broken pleural line.
- Small consolidations: consolidations (hypoechoic areas) smaller than 1 cm in diameter, surrounded by a hyperechoic artifact tail.
- Lobar consolidations: larger (over 1 cm) consolidation areas without or with the presence of air bronchograms.

A compatible LUS exam was considered a bilateral pattern of B-lines, isolated or confluent, irregular pleural lines, and/or subpleural consolidations.

The examinations were performed using a GE LOGIQ e ultrasound system fitted with a phased and curvilinear array transducer (1.5–4.5 MHz) (General Electrics Healthcare, Madrid, Spain) as a cart-based device, and a Butterfly IQ (Butterfly Network, Guilford, CT, USA) as a hand-held device.

The two sonographers were blinded to the patient’s past medical history, vital signs, symptoms, laboratory measurements and therapy. The results of the ultrasound were recorded in the patient’s medical history, and this information was available to the treating physician, who adjusted the therapy based on these findings.

Outcome measures and definitions

The main purpose of this study was to describe and characterize the POCUS findings of the disease in patients with COVID-19 admitted to the ED. The primary outcome was to determine the impact of POCUS parameters on the prognosis of patients with highly suspected or confirmed COVID-19. The secondary outcome was to correlate these parameters with the physical exam, laboratory markers, and chest X-ray.

We defined a confirmed case as any patient with clinical symptoms and positive RT-PCR, and a high suspicion case as any patient with negative RT-PCR but compatible clinical symptoms and typical X-ray, CT scan, or lung POCUS.

Statistical analysis

Baseline characteristics are presented as mean and standard deviation (SD) for continuous variables and count and proportions for categorical variables. For group comparisons, we used a t-test for continuous variables and the chi-squared or Fisher’s exact test for categorical variables. The correlations between continuous variables were tested using Spearman’s rho test for categorical variables. Mean values were reported, along with 95% confidence intervals (CIs). Statistical significance was set at p < .05.

Statistical analyses were conducted with IBM SPSS software v20.0 (SPSS Inc., Chicago, IL, USA).

Results

A total of 96 patients were enrolled between March and April 2020 (summarized in Table 1 and Fig. 2). The mean age was 68.2 years (SD 17.5), and 50 (52.1%) patients were women. Nearly half (47 [49%]) of the patients had hypertension, most receiving angiotensin-converting-enzyme inhibitors or angiotensin receptor blocker therapy. The most common presenting symptom was dyspnea (67.7%) and fever (65.6%), and the mean onset of symptoms was 6 days (SD 5.0). The patients were normotensive and had low oxygen saturation (91.8%, SD 6.1), with a respiratory rate of 15 rpm (SD 4.2), and many needed supplemental oxygen (69.7%). The mean lymphocyte count was $1.34 \times 10^3$ (SD 1.8), CRP was 106.5 (96.8%),
and LDH was 304 U/L (SD 157.1) at admission. The main therapy was hydroxychloroquine (50 patients, 60.4%).

Imaging modalities: chest X-ray and ultrasound studies

All the included patients underwent a POCUS study, and almost all of them had a chest X-ray (see Table 2).

The most frequent pattern in the chest X-ray was an interstitial pattern (56.4%), and more than one-third had ground-glass opacities (GGOs). Almost 30% of them had a normal chest X-ray.

Regarding the lung POCUS, the most common finding was an irregular pleural line (63.2%), followed by bilateral confluent (55.2%) and isolated B-lines (53.1%). Four patients had a completely normal lung ultrasound, whereas 22 (23%) patients had pleural effusion. The expiratory and inspiratory average diameters of the IVC were 14.1 (6.4) and 6.8 (6.2) mm, respectively. The FOCUS revealed a low ejection fraction in 10 patients.

After the POCUS exam, almost 20% of the patients had an associated condition that required a change in their treatment or management.

Correlation of POCUS and RT-PCR of SARS-CoV-2

The presence of irregular pleural line (see Table 3) was associated with a positive RT-PCR (odds ratio [OR] 4.327; 95% CI 1.216–11.246; p < .001), with sensitivity (S) 71.7% specificity (Sp) 65.1%, positive predictive value (PPV) 61.5%, and negative predictive value (NPV) 71.7%. The chest X-ray had 62.2%, Sp 71.4%, PPV 88.5%, and NPV 34.9% (OR 4.107; 95% CI 1.427–11.818; p = .006).

The presence of confluent B-lines was associated with a positive RT-PCR (OR 3.167; 95% CI 1.302–7.699; p = .023), with S 86.8%, Sp 32.6%, PPV 61.3%, and NPV 66.7%. Positive or indeterminate RT-PCR was associated with S 81.7%, Sp 42.9%, PPV 89.3%, and NPV 28.5% (OR 3.350; 95% CI 1.012–11.094; p = .04).

Correlation of POCUS and chest X-ray

The presence of confluent B-lines was associated with pathological findings in the chest X-ray, with S 83.8%, Sp 66.7%, PPV 89.9%, and NPV 53.8% (OR 10.333; 95% CI 3.447–30.976; p < .001). The presence of consolidations (small and lobar) was associated with a pathological X-ray, with S 73%, Sp 61.9%, PPV 87.1%, and NPV 39.4% (OR 4.388; 95% CI 1.583–12.158; p = .003).

Bilateral confluent B-lines were associated with finding of an interstitial pattern, with S 75.5%, Sp 70.7%, PPV 76.9%, and NPV 69% (OR 2.392; 95% CI 1.012–5.654; p < .001), and GGOs with S 32.4%, Sp 53.4%, NPV 72.1%, and PPV 48.1% (OR 2.392; 95% CI 1.012–5.654; p = .045).

However, we did not find any significant association between isolated B-lines and interstitial pattern (p = .156), GGO (p = .928), or any pathologic X-ray findings (p = .831).

Correlation of POCUS and laboratory parameters

There was a positive correlation between IL-6 and the number of affected areas on lung POCUS: confluent B-lines (rho = 0.622; p = .002) and irregular pleural line (rho = 0.509; p = .013). A high IVC inspiratory diameter also correlated with IL-6 (rho = 0.550; p = .007); however, a pathologic chest X-ray showed a lower correlation (rho = 0.442; p = .035). Other laboratory and inflammatory markers showed a good correlation with IL-6: CRP (rho = 0.604; p = .002), procalcitonin (rho = 0.504; p = .024), ferritin (rho = 0.579; p = .005), AST (rho = 0.635; p = .001) and LDH (rho = 0.695; p < .001). The highest correlation was found with the respiratory rate (rho = 0.789; p < .001) and N-terminal pro B-type natriuretic peptide (rho = 0.990; p = .001). These patients were more likely to receive anti-IL-6 therapy (rho = 0.612; p = .002).

We found a statistically significant negative correlation of pO2 levels with IVC diameter, both inspiratory (rho = −0.527; p = .017) and expiratory (rho = −0.539; p = .014). The IVC inspiratory diameter positively correlated with troponin I levels (rho = 0.509; p = .03).

Correlation of POCUS and therapy

Patients who showed confluent B-lines were more likely to receive anti-IL-6 therapy (rho = 0.206; p = .045), and patients who showed a lobar consolidation were more likely to receive therapy with hydroxychloroquine (rho = 0.810; p = .001). Remarkably, this correlation was much lower when small consolidations (rho = 0.252, p = .103) or confluent (rho = 0.262; p = .01) or isolated (rho = 0.279, p = .006) B-lines were present.

Correlation of POCUS and prognosis

At the end of the first week of follow-up, 6 (6.3%) patients had died and 17 (17.1%) were discharged home. The remaining 73 (76.0%) patients were still hospitalized.

Normal chest X-ray had a weak correlation with ED discharge (rho = 0.235; p = .022). Abnormal chest X-ray was not associated with mortality (p = .178) or poor outcome (ICU admission, the need for mechanical ventilation, inotropic drugs or death; p = .115). Normal lung POCUS had a moderate correlation with ED discharge.
Table 1
Demographics and clinical characteristics of patients included (N=96).

| Demographics                                      | N (%)  |
|---------------------------------------------------|--------|
| Gender (female) – N (%)                            | 50 (52.1) |
| Age (years) mean (SD)                             | 68.16 (17.5) |
| Past medical history                              | N (%)  |
| Cardiovascular disease – N (%)                    | 26 (27.1) |
| Pulmonary disease – N (%)                         | 28 (29.2) |
| Diabetes Mellitus – N (%)                         | 24 (25) |
| Chronic Kidney Disease – N (%)                    | 13 (13.5) |
| Immunosuppression – N (%)                         | 15 (15.6) |
| Hypertension – N (%)                              | 47 (49) |
| Obesity – N (%)                                   | 13 (13.5) |
| Malignancy – N (%)                                | 16 (16.7) |
| Dementia – N (%)                                  | 19 (19.8) |
| Previous antiplatelet therapy – N (%)             | 19 (19.8) |
| Previous antiplatelet therapy – N (%)             | 19 (19.8) |
| Previous anticoagulation – N (%)                  | 13 (13.5) |
| Chronic Oxygen Therapy – N (%)                    | 4 (4.2) |
| Symptoms                                          |        |
| Dyspnea – N (%)                                   | 65 (67.7) |
| Fever – N (%)                                     | 63 (65.6) |
| Myasthenia – N (%)                                | 41 (42.7) |
| Gastrointestinal symptom – N (%)                  | 14 (14.6) |
| Cough – N (%)                                     | 45 (46.9) |
| Chest Pain – N (%)                                | 25 (26) |
| Onset of symptoms (days) mean (SD)                | 6.03 (3.0) |
| Laboratory results – Mean (SD)                    |        |
| WBC > 108/μL (SD)                                 | 2.29 (1.3) |
| Lymphocytosis > 108/μL (SD)                       | 1.34 (1.8) |
| Platelets > 108/μL (SD)                           | 275.9 (132.7) |
| Creatinine – mg/dL (SD)                           | 0.85 (0.25) |
| Urea – mg/dL (SD)                                 | 31.4 (9.9) |
| ALT – U/L (SD)                                    | 31.1 (24.4) |
| Total bilirubin – mg/dL (SD)                      | 0.7 (0.4) |
| LDH – U/L (SD)                                    | 304 (173.1) |
| Lactate – mmol/L (SD)                             | 1.5 (1.1) |
| pO2 – mmHg (SD)                                   | 66.8 (18.9) |
| pCO2 – mmHg (SD)                                  | 36.9 (8.9) |
| pH (SD)                                           | 7.43 (0.08) |
| CRP – U/L (SD)                                    | 121.8 (244.1) |
| D-dimer – ng/mL (SD)                              | 5091.3 (14682) |
| PCT – ng/mL (SD)                                  | 2.43 (12.4) |
| C-Reactive Protein – mg/dL (SD)                   | 106.3 (96.8) |
| Troponin I – ng/mL (SD)                           | 27.2 (86.4) |
| NT-proBNP – pg/mL (SD)                            | 2279.8 (3443.8) |
| IL-6 – pg/mL (SD)                                 | 55.13 (63.5) |
| Ferritin – ng/mL (SD)                             | 613.6 (736.1) |
| SARS-CoV-2 (PCR) test                             | 89 (92.7) |
| Positive – N (%)                                  | 54 (60.6) |
| Negative – N (%)                                  | 28 (31.5) |
| Indeterminate – N (%)                             | 7 (7.9) |
| Therapy                                           |        |
| Hydroxychloroquine – N (%)                        | 58 (60.4) |
| Antibiotics – N (%)                               | 59 (61.5) |
| Lopinavir – N (%)                                 | 7 (7.3) |
| Tocilizumab – N (%)                               | 9 (9.4) |
| Corticosteroids – N (%)                           | 22 (22.9) |
| Oxygen – N (%)                                    | 67 (69.8) |
| Nasal Cannula – N (%)                             | 25 (26) |
| Standard oxygen mask – N (%)                      | 24 (25) |
| Non-rebreather mask – N (%)                       | 18 (19) |
| Mechanical ventilation – N (%)                    | 2 (2) |
| Norepinephrine – N (%)                            | 3 (3.1) |
| Follow-up                                         |        |
| Admission – N (%)                                 | 74 (77.1) |
| ICU – N (%)                                       | 4 (4.2) |
| Discharge – N (%)                                 | 17 (17.7) |
| Mortality – N (%)                                 | 6 (6.3) |

ACEI: Angiotensin-converting enzyme inhibitors. ARB: Angiotensin receptor blockers. CK: creatine kinase. IL-6: Interleukin 6. LDH: Lactate dehydrogenase. NT-proBNP: N-terminal pro-brain natriuretic peptide. PCT: Polymerase chain reaction. PCE: Procalcitonin; SD: standard deviation.

(rho = .444; p < .001). Abnormal lung POCUS findings were not associated with mortality (rho = .514) or poor outcome (rho = .446).

Patients with comorbid diseases were more prone to have apical lung involvement: hypertension (OR 3.040; 95% CI 1.055–8.762; p = .034), cardiomyopathy (OR 2.917; 95% CI 1.152–7.386; p = .021), and dementia (OR 4.286; 95% CI 1.492–12.310; p = .005). Although the apical lung involvement had a weak correlation with poor outcome (rho = .217; p = .034), such as mortality or need of mechanical ventilation, it was comparable to lymphocyte count (rho = −.273; p = .009), creatinine (rho = .267; p = .011), and procalcitonin (rho = .367; p = .002).

Discussion

Safety and quality are vital components in an ED patient’s management. Many hospitals are struggling to reduce ED overcrowding and to increase patient safety through multimodal interventions on patient flow in the ED, especially with laboratory and diagnostic imaging departments.13

There is growing literature regarding the prognostic factors,5 diagnosis,54, and therapeutic challenges8 in patients with COVID-19.

In diagnosis, the sensitivity of RT-PCR for diagnosing SARS-CoV-2 has been quantified as 63% in nasal swab and 32% in pharyngeal swab,12 which is similar to our results; we found a positive rate of only 59.5% in patients with clinical suspicion of COVID-19. Therefore, imaging methods play a key role in the diagnosis and assessment of these patients.

A study of 1049 patients undergoing chest CT scan and RT-PCR testing determined that CT abnormalities had a high sensitivity for diagnosing patients with COVID-19, suggesting that a CT scan should be considered as a screening tool, especially in epidemic areas with high pretest probability. However, the use of CT in the ED has many limitations, such as radiation exposure, especially for mild illness, its low availability, and the contraindication for its use in unstable patients.

Therefore, in many centers, CT scans have been replaced by chest X-ray. However, as we have seen, chest X-rays have been shown to have a very low NPV (34.9%). In a study of patients undergoing an initial screening for COVID-19, they found a sensitivity of 25% and a specificity of 90%.13

In our study, we found that of 27 patients with normal chest X-ray, 23 (85.1%) had a pathological POCUS finding. A previous study found that a normal chest X-ray was present in 31% of patients with positive RT-PCR for COVID-19,14 which is similar to our results (28.4%). We hypothesize that this low percentage is due to the low accuracy of X-ray for detecting interstitial abnormalities,2 represented in our study as isolated B-lines on lung POCUS, and becoming apparent on X-ray as the disease progresses, with the appearance of confluent B-lines and other findings.

Similar to our results, a recent prospective study, in which lung POCUS was performed on 84 patients, found that the presence of bilateral B-lines had the highest positive likelihood ratio for the diagnosis of COVID-19 (RT-PCR-positive).17

Our study, in line with early literature, suggests a valuable role for lung POCUS in patients with COVID-19, leading to early correct diagnoses and appropriate management, particularly in triage.18

Regarding therapy, by adding POCUS to our protocol, we could determine the presence of synchronous or comorbid diseases, such as heart failure or lobar pneumonia (viral or bacterial), or confirm the presence of deep vein thrombosis or pericardial effusion, which in our study was observed in approximately 1 of 5 (18.8%) patients. These findings should trigger the initiation or adjustment of therapy (e.g., antibiotics, anticoagulants, diuretics, or colchicine).
Table 2

Imaging modalities (Chest X-ray and Point-of-Care Ultrasound) findings of patients included (N=96), with or without positive test on RT-PCR. RT-PCR not performed in 7 patients.

| Imaging modalities | TOTAL (%) | RT-PCR+ (N=54) | RT-PCR− or indeterminate (N=35) | p-Value |
|--------------------|-----------|----------------|-------------------------------|---------|
| Chest X-ray        | 95 (99)   | 53 (98.1)      | 35 (100)                      |         |
| Bilateral − (%)    | 27 (28.4) | 6 (11.1)       | 11 (31.4)                     | 0.019   |
| Ground-Glass Opacity (GGO) − (%) | 37 (38.9) | 23 (42.6)      | 14 (40.0)                     | 0.752   |
| Intersitial Pattern − (%) | 53 (56.4) | 37 (68.5)      | 14 (40.0)                     | 0.008   |
| Unilobar − (%)     | 11 (11.6) | 7 (12.9)       | 3 (8.6)                       | 0.112   |
| Bilateral − (%)    | 7 (7.4)   | 4 (7.4)        | 3 (8.6)                       | 0.112   |
| Bilateral − (%)    | 50 (52.7) | 34 (62.7)      | 16 (45.7)                     |         |

Point-of-care ultrasonography (POCUS) results

| Normal − N (%)     | 96 (100)  | 54 (100)       | 35 (100)                      | 0.324   |
| Left pleural effusion − N (%) | 15 (15.6) | 5 (9.3)        | 10 (28.6)                     | 0.017   |
| Right pleural effusion − N (%) | 12 (12.5) | 6 (11.1)       | 6 (17.1)                      | 0.416   |
| Bilateral isolated B-lines − N (%) | 51 (53.1) | 34 (63.0)      | 17 (48.6)                     | 0.180   |
| Isolated B-lines − # affected areas (SD) | 2.5 (2.2) | 3.0 (2.2)      | 2.1 (2.2)                     | 0.648   |
| Bilateral Confluent B-lines − N (%) | 53 (55.2) | 38 (70.4)      | 15 (42.9)                     | 0.010   |
| Confluent B-lines − # affected areas (SD) | 3 (3.2)   | 3.9 (2.9)      | 3.1 (2.2)                     | 0.185   |
| Bilateral Irregular Pulmonary Line − N (%) | 61 (63.2) | 38 (70.4)      | 22 (62.9)                     | 0.460   |
| Irregular pleural line − # affected areas (SD) | 3.5 (2.6) | 3.8 (2.3)      | 3.6 (3.1)                     | 0.073   |
| Bilateral Small Consolidations − N (%) | 42 (43.8) | 25 (46.3)      | 17 (48.6)                     | 0.834   |
| Small consolidations − # affected areas (SD) | 2.3 (2.4) | 2.2 (2.4)      | 2.8 (2.5)                     | 0.527   |
| Pneumonia (lobar consolidation) − N (%) | 13 (13.5) | 10 (18.5)      | 3 (8.6)                       | 0.194   |
| Low Ejection Fraction − N (%) | 10 (10.4) | 5 (9.3)        | 5 (14.3)                      | 0.463   |
| Ventricular Dilation − N (%) | 5 (5.2)   | 1 (1.9)        | 4 (11.4)                      | 0.55    |
| Atrial dilation − N (%) | 20 (20.8) | 12 (22.2)      | 8 (22.9)                      | 0.54    |
| Ventricular hypertrophy − N (%) | 21 (21.9) | 10 (18.5)      | 11 (31.4)                     | 0.161   |
| Right overload − N (%) | 12 (12.5) | 8 (14.8)       | 4 (11.4)                      | 0.648   |
| Valvulopathy − N (%) | 36 (37.5) | 21 (38.9)      | 15 (42.9)                     | 0.709   |
| Pericardial effusion − N (%) | 16 (16.7) | 10 (18.5)      | 6 (17.1)                      | 0.869   |
| IVC max (mm) (SD) | 14.1 (6.4) | 13.7 (6.3)     | 14.1 (6.9)                    | 0.320   |
| IVC min (mm) (SD) | 6.8 (6.2)  | 6.3 (5.9)      | 7.4 (7.1)                     | 0.045   |
| Lung POCUS total findings* (SD) | 3.3 (1.4) | 3.6 (1.1)      | 3.3 (1.4)                     | 0.165   |

Change/Amendment to diagnosis − N (%) after POCUS

| Acute pericarditis − N (%) | 18 (18.8) | 11 (20.4)      | 7 (20.0)                      | 0.966   |
| Decompensated heart failure − N (%) | 4 (4.2)   | 4 (7.5)        | 0 (0)                         | 0.152   |
| Bacterial superinfection − N (%) | 7 (7.3)   | 3 (5.6)        | 4 (11.4)                      | 0.315   |
| PE/DVT − N (%) | 3 (3.1)   | 3 (5.6)        | 0 (0)                         | 0.276   |

DVT: deep vein thrombosis; GGO: Ground-Glass Opacity; IVC: inferior vena cava; pulmonary embolism; POCUS: point-of-care ultrasonography; SD: standard deviation.

* Lung POCUS total findings: pleural effusion, isolated B lines, confluent B lines, irregular pleural line, small consolidation, lobar consolidation.

Table 3

Correlation of POCUS findings and positive RT-PCR.

| POCUS results | POSITIVE RT-PCR (OR) | CI 95% inferior | CI 95% Superior |
|---------------|----------------------|----------------|----------------|
| Abnormal      | 3.212                | 0.280          | 36.834         |
| Left pleural effusion | 0.255              | 0.079          | 0.827          |
| Right pleural effusion | 0.604              | 0.178          | 2.050          |
| Bilateral isolated B-lines | 1.800              | 0.760          | 4.266          |
| Bilateral confluent B-lines | 3.167              | 1.302          | 7.699          |
| Bilateral irregular pleural line | 1.403              | 0.570          | 3.454          |
| Bilateral small consolidations | 0.913              | 0.389          | 2.139          |
| Low ejection fraction | 0.612              | 0.164          | 2.292          |
| Ventricular dilation | 0.146              | 0.16           | 1.368          |
| Atrial dilation | 0.964                | 0.349          | 2.666          |
| Ventricular hypertrophy | 0.496              | 0.184          | 1.335          |
| Right overload | 1.348                | 0.373          | 4.866          |
| Valvulopathy | 0.848                | 0.357          | 2.014          |
| Pericardial effusion | 1.098              | 0.360          | 3.351          |
| Pleural effusion | 0.333              | 0.120          | 0.929          |
| Isolated B-lines | 2.324                | 0.775          | 6.967          |
| Confluent B-lines | 2.017                | 0.749          | 5.429          |
| Small consolidations | 0.871              | 0.343          | 2.210          |
| Irregular pleural line | 4.327              | 1.216          | 15.401         |

CI: Confidence Interval; OR: Odds Ratio; POCUS: point-of-care ultrasonography; RT-PCR: reverse transcription polymerase chain reaction of the nucleic acid of SARS-CoV-2. Bold values denote statistical significance at the p < 0.05 level.

Moreover, we showed that that the number of affected lung areas correlated with inflammatory markers, such as IL-6, which in turn could serve as a guide to start therapy with an anti-IL-6 therapy (e.g., tocilizumab). Remarkably, but understandably, this marker was associated with a higher respiratory rate, acute phase reactants (CRP, procalcitonin, ferritin) and LDH, which according to previous studies are also prognostic markers. We did not observe a correlation with ICU admission, therapeutic or invasive procedures, or death, possibly due to the short follow-up (1 week).

Evidence in follow-up and prognosis, dynamic changes in chest CT findings (GGO lesions, crazy-paving pattern, and consolidation) have been proposed to occur during the time course and
progression of the disease, which could be a marker of the disease stage. Given this disease tends to have a rapid progression, a CT scan might not be available, or the patient’s condition might not allow its performance. As previously reported in the COVID-19 era, there is a correlation between Lung POCUS findings and those of the CT scan; therefore, follow-up could be more easily replaced with POCUS because it would be more accessible. This possibility should be explored in future studies.

The presence of apical lung involvement in POCUS correlated in our study with various comparable comorbid diseases (hypertension, cardiomyopathy, dementia) that yielded specific laboratory markers (creatinine, lymphocyte count, procalcitonin), and as expected, prognoses.

The IVC, as a marker of fluid status, moderately correlated with levels of pO2 and troponin I, which could represent hemodynamic congestion (higher inspiratory and expiratory diameters) and poorer oxygenation. Therefore, we believe that integrating IVC into our current practice is appropriate, given it more physiologically addresses the assessment of the volume status.

In our study, we found a higher prevalence of pleural effusion (23%) than previously reported, which could be due to the accuracy of the technique compared with CT scan or chest X-ray; therefore, its mere presence should not be considered as a prognostic factor.

The main strengths of our study, is that to our knowledge, this is the first study evaluating the potential impact of POCUS on patients with COVID-19, with diagnostic, prognostic, and therapeutic implications.

We would like to share our study findings, given the urgent need for various strategies in order to better manage patients with COVID-19, and to diminish the SARS-CoV-2 spread and its prognosis in the current pandemic context. Given the shortage of resources constitutes an undeniable public health threat, we consider POCUS to be a potential solution, and recommend that it be performed as a first-line imaging test for patients with COVID-19.

There are several limitations to consider. The main limitation is that lung POCUS findings overlap with those from other pneumonia etiologies or incidental chronic findings (e.g., chronic heart failure or pulmonary fibrosis). In epidemic areas, however, positive lung POCUS features, even with negative RT-PCR or chest X-ray, can still be highly suggestive of COVID-19 infection, which could preclude that the sensitivity and specificity reported of lung POCUS might be higher. Thus, more studies should be performed comparing it with other techniques (e.g., CT scan). Many patients with COVID-19 in our ED with negative RT-PCR or chest X-ray do not always receive a chest CT, and therefore there is a chance of misdiagnosis. This limitation was minimized, given the patients were followed-up by reviewing their electronic history, and any complications were recorded. In addition, we have to highlight that the main purpose of the study was to compare the performance of POCUS in COVID-19 patients, and the study was not powered to evaluate the performance of a diagnostic or management strategy based on POCUS findings; therefore, for this purpose, the study can only be considered hypothesis generating.

Another limitation is that selection bias might have occurred. Two expert sonographers performed all ultrasound scans on a consecutive sample selected based on their availability (during their working hours), which limits the generalizability of our results. The impact of this limitation is minimized by variable schedules and changing shifts, unpredictable a priori (in continuous care). Additionally, false negative ultrasounds might be found in the initial stage of the disease, before lung involvement.

Thus, the results from this study provide an opportunity to further investigate the use of ultrasound in various settings and clinical scenarios.

In conclusion, in this pandemic era, given the shortage of resources constitutes an undeniable public health threat, POCUS presents the potential to impact the diagnosis, management, and prognosis of patients with confirmed or suspected COVID-19.

Authors’ contribution

Conception and design: YTC. Analysis and interpretation: YTC. Data collection: YTC, PRF, RFF, ESR, BAM. Writing the article: YTC, ALM. Critical revision of the article: YTC, PRF, RFF, ALM. Final approval of the article: YTC, PRF, RFF, ALM, ESR, BAM, AMV, ARN. Statistical analysis: YTC, ALM. Overall responsibility: YTC.

Ethics

All authors read and approved the final manuscript. This work has not been supported by public grants or financial support. No sources of funding were used to assist in the preparation of this study. Each author certifies that he has no commercial associations that might pose a conflict of interest in connection with the submitted article. We certify that this research was conducted in conformity with ethical principles of our institution. This work, figures and tables, have not been previously published and reproduced from another source.

Data access and responsibility

The principal investigator, Yale Tung Chen, had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Funding

This research received no external funding.

Conflict of interest

The authors declare that they have no conflict of interest.

Acknowledgments

The authors have declared no conflicts of interest.

Appendix A. Article summary:

1. Why is this topic important?

Coronavirus Disease 2019 (COVID-19) is a highly contagious illness caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In this pandemic era, with the low sensitivity of diagnostic tests and a shortage or difficult-to-access resources, such as CT scan, specific laboratory markers such as IL-6 or therapy, and the lack of reliable prognostic markers (e.g., need for ICU admission or mechanical ventilation), constitutes an undeniable public health threat.

The role of point-of-care ultrasonography (POCUS) has yet to be explored.

2. What does this study attempt to show?

We aimed to describe and characterize the POCUS findings in patients with COVID-19 admitted to the emergency department (ED), to correlate these parameters with vital signs, laboratory prognostic markers, and chest X-ray.
3. What are the key findings?

- Diagnostic: POCUS findings correlated with the result of the reverse transcription-polymerase chain reaction (RT-PCR) and chest X-ray abnormalities.
- Therapeutic: After POCUS, approximately 20% of the patients had an associated condition that required a change in their treatment or management. POCUS findings correlated with IL-6 levels (potential therapy with anti-IL-6).
- Prognostic: Apical involvement in lung POCUS correlated with a poor outcome (ICU admission, need for mechanical ventilation, inotropic drugs, and death). IVC correlated with troponin I and levels of pO2.

4. How is patient care impacted?

Diagnostic imaging plays a key role in the management of patients with COVID–19, and POCUS might be a potential solution to the limitations in the various strategies used to manage these patients. We recommend that POCUS should be performed as a first-line imaging test for patients with COVID-19.

References

1. World Health Organization. Rolling updates on coronavirus (COVID-19); 2020. WHO characterizes COVID-19 as a pandemic. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/events-as-they-happen [accessed 31.07.20].
2. Johns Hopkins Coronavirus Resource Center; 2020. Available from https://coronavirus.jhu.edu/map.html [accessed 12.10.20].
3. Guidance for Corona Virus Disease 2019: Prevention, Control, Diagnosis and Management National Health Commission (NHC) of the PRC, General Office; National Administration of Traditional Chinese Medicine of the PRC, General Office; 2020. Available from: http://www.nmpm.com/ [accessed 31.07.20].
4. Al T, Yang Z, Hou H, Zhan C, Chen C, Lv W, et al. Correlation of Chest CT and RT-PCR Testing in Coronavirus Disease 2019 (COVID-19) in China: a report of 1014 cases. Radiology. 2020;296:E32–40. http://dx.doi.org/10.1148/radiol.2020200642.
5. Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382:1708–20. http://dx.doi.org/10.1056/NEJMoa2002032.
6. Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19) 2019; a review. JAMA [Internet]. 2020;323:1824–36. http://dx.doi.org/10.1001/jama.2020.0619.
7. Volpicelli C, Lamorte A, Vilîen T. What’s new in lung ultrasound during the COVID-19 pandemic. Intensive Care Med. 2020;46:1445–8. http://dx.doi.org/10.1007/s00134-020-06048-9.
8. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506. http://dx.doi.org/10.1016/S0140-6736(20)30183-5.
9. Liu RB, Tayal VS, Panebianco NL, Tung-Chen Y, Nagdev A, Shah S, et al. Ultrasound on the frontlines of COVID-19: report from an International Webinar. Acad Emerg Med. 2020;27:523–6. http://dx.doi.org/10.1111/acem.14004.
10. Ultrasound guidelines: emergency, point-of-care and clinical ultrasound guidelines in medicine. Ann Emerg Med. 2017;69:e27–54. http://dx.doi.org/10.1016/j.annemergmed.2016.08.457.
11. Soumer A, Perbet S, Brisson H, Arbelot C, Constantin J-M, Lu Q, et al. Ultrasound assessment of lung aeration loss during a successful weaning trial predicts postextubation distress. Crit Care Med. 2012;40:2064–72. http://dx.doi.org/10.1097/CCM.0b013e31824e68ae.
12. Volpicelli C, Elbarbary M, Blayvas M, Lichtenstein DA, Mathis G, Kirkpatrick AW, et al. International evidence-based recommendations for point-of-care lung ultrasound. Intensive Care Med. 2012;38:577–91, http://dx.doi.org/10.1007/s00134-012-2513-4.
13. Shaw JLV. Practical challenges related to point of care testing. Pract Lab Med. 2015;4:22–9. http://dx.doi.org/10.1016/j.plabm.2015.12.002.
14. Wang W, Xu Y, Gao R, Lu R, Han K, Wu G, et al. Detection of SARS-CoV-2 in different types of clinical specimens. JAMA. 2020;323:1843–4. http://dx.doi.org/10.1001/jama.2020.3786.
15. Choi H, Qi X, Yoon SH, Park SJ, Lee KH, Kim JY, et al. Extension of Coronavirus Disease 2019 (COVID-19) on chest CT and implications for chest radiograph interpretation. Radiol Cardthoracic Imag. 2020;2:e200107. http://dx.doi.org/10.1148/ryct.2020200107.
16. Wong HYF, Lam HYS, Fong AH-T, Leung ST, Chin TW-Y, Lo CSY, et al. Frequency and distribution of chest radiographic findings in COVID-19 positive patients. Radiology. 2020;296:E72–8. http://dx.doi.org/10.1148/radiol.2020201160.
17. Peyrony O, Marbeuf-Gueye C, Truong V, Giroud M, Rivière C, Khenissi K, et al. Accuracy of Emergency Department clinical findings for diagnosis of coronavirus disease-2019. Ann Emerg Med. 2020;76:405–12. http://dx.doi.org/10.1016/j.annemergmed.2020.05.022.
18. Piliego C, Strumia A, Stone MB, Pascarella G. The ultrasound guided triage: a new tool for prehospital management of COVID-19 pandemic. Anesth Analg [Internet]. 2020;131:e93–4. http://dx.doi.org/10.1213/ANE.0000000000004940.
19. Pan F, Ye T, Sun P, Gui S, Liang B, Li L, et al. Time course of lung changes on chest CT during recovery from 2019 novel coronavirus (COVID-19) pneumonia. Radiology. 2020;295:715–21. http://dx.doi.org/10.1148/radiol.2020200370.
20. Bernheim A, Mei X, Huang M, Yang Y, Fayad ZA, Zhang N, et al. Chest CT findings in Coronavirus Disease-19 (COVID-19): relationship to duration of infection. Radiology. 2020;295:200463. http://dx.doi.org/10.1148/radiol.2020200463.
21. Poggiali E, Dacremia A, Bartoni D, Tinelli V, Demichele E, Mateos Ramos P, et al. Can lung US help critical care clinicians in the early diagnosis of novel coronavirus (COVID-19) pneumonia? Radiology. 2020;295:E6. http://dx.doi.org/10.1148/radiol.2020200847.
22. Peng Q-Y, Wang X-T, Zhang L-N, Chinese Critical Care Ultrasound Study Group (CCUSCG). Findings of lung ultrasonography of novel corona virus pneumonia during the 2019–2020 epidemic. Intensive Care Med. 2020;46:849–50. http://dx.doi.org/10.1007/s00134-020-05996-6.